Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.5%

1 terminated/withdrawn out of 22 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
11(50.0%)
Phase 1
7(31.8%)
N/A
3(13.6%)
Phase 3
1(4.5%)
22Total
Phase 2(11)
Phase 1(7)
N/A(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT05848713Phase 3Recruiting

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Role: collaborator

NCT06370832Not ApplicableRecruiting

Inspiratory Muscle Training in Lung Transplant Candidates

Role: collaborator

NCT02743741Not ApplicableActive Not Recruiting

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Role: collaborator

NCT02483312Phase 1Active Not Recruiting

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Role: collaborator

NCT02750670Phase 2Completed

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Role: collaborator

NCT04202835Phase 2Active Not Recruiting

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Role: collaborator

NCT06613217Phase 1Recruiting

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

Role: collaborator

NCT03027102Phase 1Completed

Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia

Role: collaborator

NCT06650709Phase 2Not Yet Recruiting

NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study

Role: collaborator

NCT04944173Phase 2Withdrawn

SCION: SABR and Checkpoint Inhibition of NSCLC

Role: collaborator

NCT06331455Phase 2Recruiting

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection

Role: collaborator

NCT06222788Not ApplicableNot Yet Recruiting

Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)

Role: collaborator

NCT02800070Phase 1Completed

Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease

Role: collaborator

NCT04543110Phase 2Unknown

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

Role: collaborator

NCT02569645Phase 2Completed

Rosuvastatin in the Treatment of Rectal Cancer

Role: collaborator

NCT02599779Phase 2Completed

A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients

Role: collaborator

NCT01310231Phase 2Completed

A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer

Role: lead

NCT00966472Phase 1Completed

Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC

Role: collaborator

NCT02268370Phase 2Unknown

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Role: collaborator

NCT03283943Phase 1Unknown

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Role: collaborator